>
>
Investor call and webcast scheduled for Monday, August 15 at 8:00 a.m. EDT Roivant will host an investor day on Wednesday, September 28 at 11:00
Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity
Investor call and webcast scheduled for Tuesday, June 28 at 8:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 15, 2022 (GLOBE
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, May 19, 2022 (GLOBE NEWSWIRE) — Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare
Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxis Tapinarof was
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 11, 2022 (GLOBE NEWSWIRE) — Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt
Conference call today at 8:00am ET VANCOUVER, British Columbia and CAMBRIDGE, Mass. and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) — Genevant Sciences, a leading
Roivant’s newly launched subsidiary, Hemavant, entered into a licensing agreement with Eisai Co., Ltd. for exclusive global rights to the investigational agent RVT-2001, a potential
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) — Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt
Roivant will develop RVT-2001 for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes Roivant JPM presentation scheduled for Monday, January 10,
